News
GLMD
--
0.00%
--
Galmed Pharmaceuticals Q3 EPS $(0.32) Misses $(0.30) Estimate
Galmed Pharmaceuticals (NASDAQ:GLMD) reported quarterly losses of $(0.32) per share which missed the analyst consensus estimate of $(0.30) by 6.67 percent. This is a 52.38 percent decrease over losses of $(0.21) per
Benzinga · 11/12 12:07
Galmed EPS misses by $0.02
Galmed (GLMD): Q3 GAAP EPS of -$0.32 misses by $0.02.Cash and cash equivalents, restricted cash, short-term deposits and marketable debt securities of $58.7MPress Release
Seekingalpha · 11/12 12:07
Galmed Pharmaceuticals Ltd. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / November 12, 2020 / Galmed Pharmaceuticals Ltd.
ACCESSWIRE · 11/12 11:45
Galmed and MyBiotics to Collaborate in Development of Bespoke Microbiome Signature for Aramchol
Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) and MyBiotics Pharma Ltd. announced today they have entered into a research and development collaboration agreement to identify and optimize the selected microbiome repertoire associated with the response to Aramchol. The research will also focus on development of a standalone microbiome-based treatment for non alcoholic steatohepatitis (NASH) and fibrosis.
PR Newswire · 11/09 13:00
We're Hopeful That Galmed Pharmaceuticals (NASDAQ:GLMD) Will Use Its Cash Wisely
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Simply Wall St. · 10/20 13:31
Galmed and Gannex Expand Development Programs For NASH Through Research Collaboration of Aramchol and ASC41 (THR-beta Agonist)
Gannex Pharma Co., Ltd., a wholly owned company of Ascletis Pharma Inc. (HKEX: 1672) and Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) announces today that they have entered into a research agreement aiming at combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment
PR Newswire · 09/10 12:49
Gannex And Galmed Announce Research Collaboration For Aramchol And ASC41
SHANGHAI and TEL-AVIV, Israel, Sept. 9, 2020 /PRNewswire/ -- GannexPharma Co., Ltd., a wholly owned company of Ascletis Pharma Inc. (HKEX: 1672) and Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) announces
Benzinga · 09/09 10:33
Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q2 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 08/09 17:23
Galmed EPS beats by $0.06
Galmed (NASDAQ:GLMD): Q2 GAAP EPS of -$0.26 beats by $0.06. As of June 30, 2020, cash and equivalents of $5.55M vs. $15.93M as of December 31, 2019. Press
seekingalpha · 08/06 16:03
Galmed Pharmaceuticals Announces Acceleration of its New Clinical Amilo-5MER program
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases provides today updated information on the Company's pipeline program.
PR Newswire · 08/06 10:50
64 Biggest Movers From Yesterday
Gainers InnerWorkings, Inc. (NASDAQ: INWK) shares jumped 115.9% to close at $2.85 on Thursday after HH Global announced plans to acquire the company for $3 per share.
Benzinga · 07/17 09:08
3 Healthcare Stocks Under $5 With Triple-Digit Upside Potential
On Wall Street, some things never change. Public health crisis or not, the fact of the matter remains that healthcare stocks are the epitome of risk/reward plays. Why? It comes down to the nature of the industry itself. Healthcare companies are unique in that
TipRanks · 07/14 21:31
Here is What Hedge Funds Think About Galmed Pharmaceuticals Ltd (GLMD)
Insider Monkey · 07/06 12:55
Inventiva SA Starts U.S. IPO Rollout
Seeking Alpha - Article · 06/26 19:52
Edited Transcript of GLMD earnings conference call or presentation 14-May-20 12:30pm GMT
Q1 2020 Galmed Pharmaceuticals Ltd Earnings Call
Thomson Reuters StreetEvents · 06/26 10:42
Benzinga's Top Upgrades, Downgrades For May 22, 2020
Upgrades
Benzinga · 05/22 14:00
B. Riley FBR Downgrades Galmed Pharmaceuticals to Neutral, Lowers Price Target of $8
B. Riley FBR analyst Mayank Mamtani downgrades Galmed Pharmaceuticals (NASDAQ:GLMD) from Buy to Neutral and lowers the price target from $11 to $8.
Benzinga · 05/22 10:03
Galmed Pharmaceuticals downgraded to neutral from buy at B. Riley FBR
marketwatch.com · 05/22 07:50
61 Biggest Movers From Yesterday
Gainers Nano Dimension Ltd. (NASDAQ: NNDM) shares surged 341.7% to close at $3.40 on Tuesday. HENSOLDT and Nano Dimension achieved a major breakthrough in electronics 3D printing.
Benzinga · 05/20 08:50
Raymond James Maintains Outperform on Galmed Pharmaceuticals, Lowers Price Target to $20
Raymond James maintains Galmed Pharmaceuticals (NASDAQ:GLMD) with a Outperform and lowers the price target from $25 to $20.
Benzinga · 05/15 12:31
Webull provides a variety of real-time GLMD stock news. You can receive the latest news about Galmed Pharma through multiple platforms. This information may help you make smarter investment decisions.
About GLMD
Galmed Pharmaceuticals is a Israeli-based clinical-stage biopharmaceutical company.The activiti of the Company is focused on the development therapy for treating liver diseases. Arachmol, the main product of Galmed Pharmaceuticals, is a liver-targeted stearoyl-coenzyme A desaturase1 used in oral therapy for the treatment of NASH (Non-alcoholic Steatohepatitis).
More